연구동향 분석

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea

이무현 한원식 이정언 김구상 박희승 김종진 배수연 신현주 이종원 이은숙 2015년

논문상세정보
인용/피인용
' The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • adjuvant chemotherapy
  • breast neoplasms
  • oncotype dx
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,372 0

0.0%

' The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea' 의 참고문헌

  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features
    Geradts J Cancer Invest 28 : 969 ~ 977 [2010]
  • The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features
    Geradts J Cancer Invest 28 969-977 [2010]
  • The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy
    Geffen DB Ann Oncol 22 : 2381 ~ 2386 [2011]
  • The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy
    Geffen DB Ann Oncol 22 2381-2386 [2011]
  • The impact of a genomic assay(Oncotype DX)on adjuvant treatment recommendations in early breast cancer
    de Boer RH Med J Aust 199 : 205 ~ 208 [2013]
  • The impact of a genomic assay(Oncotype DX)on adjuvant treatment recommendations in early breast cancer
    de Boer RH Med J Aust 199 205-208 [2013]
  • The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
    Ademuyiwa FO Breast Cancer Res Treat 126 : 797 ~ 802 [2011]
  • The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort
    Ademuyiwa FO Breast Cancer Res Treat 126 797-802 [2011]
  • The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists
    Joh JE Oncologist 16 : 1520 ~ 1526 [2011]
  • The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists
    Joh JE Oncologist 16 1520-1526 [2011]
  • The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, nodenegative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
    Eiermann W Ann Oncol 24 : 618 ~ 624 [2013]
  • The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, nodenegative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
    Eiermann W Ann Oncol 24 618-624 [2013]
  • TAILORx : trial assigning individualized options for treatment(Rx)
    Sparano JA Clin Breast Cancer 7 : 347 ~ 350 [2006]
  • TAILORx : trial assigning individualized options for treatment(Rx)
    Sparano JA Clin Breast Cancer 7 347-350 [2006]
  • Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    Goldhirsch A Ann Oncol 22 : 1736 ~ 1747 [2011]
  • Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    Goldhirsch A Ann Oncol 22 1736-1747 [2011]
  • Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive(ER+)nodenegative breast cancer
    Albanell J Ann Oncol 23 : 625 ~ 631 [2012]
  • Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive(ER+)nodenegative breast cancer
    Albanell J Ann Oncol 23 625-631 [2012]
  • Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection
    Lo SS J Clin Oncol 28 : 1671 ~ 1676 [2010]
  • Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection
    Lo SS J Clin Oncol 28 1671-1676 [2010]
  • Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Goldstein LJ J Clin Oncol 26 : 4063 ~ 4071 [2008]
  • Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features
    Goldstein LJ J Clin Oncol 26 4063-4071 [2008]
  • Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Aebi S Ann Oncol 22 (Suppl 6) : 12 ~ 24 [2011]
  • Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Aebi S Ann Oncol 22 Suppl 6 12-24 [2011]
  • National Comprehensive Cancer Network Practice Guidelines in Oncology. Breast Cancer (version v3, 2013)
  • Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation
    Biroschak JR Breast J 19 : 269 ~ 275 [2013]
  • Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation
    Biroschak JR Breast J 19 269-275 [2013]
  • Histopathologic variables predict Oncotype DX recurrence score
    Flanagan MB Mod Pathol 21 : 1255 ~ 1261 [2008]
  • Histopathologic variables predict Oncotype DX recurrence score
    Flanagan MB Mod Pathol 21 1255-1261 [2008]
  • Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer
    Paik S J Clin Oncol 24 : 3726 ~ 3734 [2006]
  • Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer
    Paik S J Clin Oncol 24 3726-3734 [2006]
  • Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    Hornberger J Am J Manag Care 11 : 313 ~ 324 [2005]
  • Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    Hornberger J Am J Manag Care 11 313-324 [2005]
  • Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J Am J Surg 196 : 527 ~ 529 [2008]
  • Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J Am J Surg 196 527-529 [2008]
  • Costeffectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
    Tsoi DT Oncologist 15 : 457 ~ 465 [2010]
  • Costeffectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer
    Tsoi DT Oncologist 15 457-465 [2010]
  • Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010
    정규원 Cancer Research and Treatment 45 (1) : 1 ~ 14 [2013]
  • Cancer Statistics in Korea: Incidence, Mortality, Survival and Prevalence in 2010
    정규원 Cancer Research and Treatment 45 1 1-14 [2013]
  • Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J Arch Pathol Lab Med 134 : 1697 ~ 1701 [2010]
  • Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score?
    Auerbach J Arch Pathol Lab Med 134 1697-1701 [2010]
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score
    Kamal AH Oncologist 16 : 1359 ~ 1366 [2011]
  • Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score
    Kamal AH Oncologist 16 1359-1366 [2011]
  • Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : a population-based study
    Wolf I Cancer 112 : 731 ~ 736 [2008]
  • Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients : a population-based study
    Wolf I Cancer 112 731-736 [2008]
  • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Harris L J Clin Oncol 25 : 5287 ~ 5312 [2007]
  • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Harris L J Clin Oncol 25 5287-5312 [2007]
  • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik S N Engl J Med 351 : 2817 ~ 2826 [2004]
  • A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Paik S N Engl J Med 351 2817-2826 [2004]